Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
Joshua A. Hill(Infectious Disease Research Institute), Daniel Li, Kevin A. Hay(University of British Columbia), Margaret L. Green(Infectious Disease Research Institute), Sindhu Cherian(University of Washington), Xueyan Chen(University of Washington), Stanley R. Riddell(University of Washington), David G. Maloney(University of Washington), Michael Boeckh(Infectious Disease Research Institute), Cameron J. Turtle(University of Washington)
Cited by 564Open Access
Abstract
cells per kg) had a higher infection density within 28 days in an adjusted model of baseline characteristics. Cytokine release syndrome (CRS) severity was the only factor after CAR-T-cell infusion associated with infection in a multivariable analysis. The incidence of infections was comparable to observations from clinical trials of salvage chemoimmunotherapies in similar patients. This trial was registered at www.clinicaltrials.gov as #NCT01865617.
Related Papers
No related papers found
Powered by citation graph analysis